Neoantigen Targeted Therapies Market is estimated to be worth USD 3 Billion in 2030

Advances in bioinformatics and genomic data analysis have enabled the identification of cancer antigens that are generally overlooked during immune surveillance; these neoantigens have been shown to possess substantial therapeutic potential

Roots Analysis is pleased to announce the publication of its recent study, titled, “Neoantigen Targeted Therapies Market, 2019-2030.”

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of developers engaged in the development of neoantigen targeted therapies.
  • Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products).
  • A detailed publication analysis of close to 300 peer-reviewed, scientific articles published during the period 2015-2019 (till February), highlighting the research focus within the industry.
  • An in-depth analysis of the various patents that have been filed / granted related to neoantigens.
  • An analysis of the various partnerships pertaining to neoantigen targeting therapies.
  • An analysis of the investments made at various stages of development in companies that are focused on developing neoantigen targeted therapies.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Target Disease Indication

  • Bone and Cartilage Cancer
  • Colorectal Cancer
  • Head and Neck Cancer
  • Renal Carcinoma
  • Hepatocellular Carcinoma
  • Lung Cancer
  • Gynecological Cancer
  • Others

Type of Treatment

  • Personalized
  • Off-the-shelf

Type of Immunotherapy

  • Dendritic Cell Vaccine
  • DNA / RNA-based Vaccine
  • Protein / Peptide-based Vaccine
  • TIL-based Therapy

Route of Administration

  • Intradermal
  • Intravenous
  • Subcutaneous
  • Others

Key Geographical Region

  • North America (US)
  • Europe (UK, Germany, France, Italy, and Spain
  • Rest of the World

Transcripts of interviews held with the following senior level representatives of stakeholder companies:

  • Gabriel Nistor, Chief Scientific Officer, AIVITA Biomedical
  • Ella Sorani, Vice President Research and Development, BioLineRx
  • Heinz Lubenau, Chief Operating Officer and Co-Founder, VAXIMM

Key companies covered in the report

  • Bavarian Nordic
  • Genocea Biosciences
  • Gradalis
  • Immunicum
  • Immunovative Therapies
  • Iovance Biotherapeutics
  • Medigene
  • Neon Therapeutics
  • Precision Biologics
  • Vaxon Biotech

Get an Exclusive PDF Sample

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.

Contact : Roots Analysis Private Limited